Pre-symptomatic biomarkers and their utility in predicting phenoconversion to clinically manifest ALS
Thu, Oct 15
|Zoom Webinar
Dr Michael Benatar, founder of the long running Pre-FALS study of at risk genetic carriers of ALS genes, will share details about a recent publication describing a new biomarker panel to predict phenoconversion to ALS.
Time & Location
Oct 15, 2026, 1:00 PM – 2:00 PM
Zoom Webinar
Guests
About the event
A recent publication from the University of Miami lab of Dr Micael Benatar is "Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS" https://www.nature.com/articles/s41591-026-04528-x is just the latest development from his long standing work studying the at risk period in those at elevated genetic risk of ALS. You can learn more about his NIH supported study here https://als-research.org/research-study/pre-fals-pre-symptomatic-familial-als-study/ .
Tickets
Zoom Link
Zoom Webinar Address- Please do not share : https://zoom.us/j/97365354909?pwd=ySKvZkIsEBoIUK7P3fdmwCiRxWbXZ7.1
$0.00
Total
$0.00